BTIG raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps a Buy rating on the shares. Guardant unveiled its much awaited V2 data for its FDA-cleared, blood-based Shield colon cancer screening test, and BTIG is “pleased” to see that Guardant demonstrated a 1-point improvement in overall sensitivity, and a significant 7-point improvement on stage 1 sensitivity, at the same level of specificity, the analyst tells investors in a research note. The news builds upon the firm’s view that Guardant is the pioneer and market leader in liquid biopsy, and Guardant remains the firm’s Top Pick for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health down 7% after reporting results of Shield V2 algorithm
- Guardant Health stock decline after data a ‘bit’ overdone, says Raymond James
- Guardant Health falls -8.3%
- Cathie Wood Continues to Sell Roku, Invests $13M in CRISPR and Intellia
- Cathie Wood Sells Shopify and Coinbase Stocks, Adds to PagerDuty (PD) Stake